Cristina Gasparetto, MD

Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 9058 North Pavilion, Durham, NC 27710
Phone (919) 668-1017
Email address gaspa001@mc.duke.edu

Dr. Gasparetto performs both laboratory and clinical research in the field of multiple myeloma. Her primary research interests are in developing immunotherapy approaches to treating multiple myeloma particularly in conjunction with hematopoietic stem cell transplantation. Ongoing laboratory research projects include the development of dendritic cell vaccines and antibody therapies. Clinical studies include a recently approved trial involving vaccination with autologous dendritic cells pulsed with idiotypic protein following high dose chemotherapy and autologous peripheral blood stem cells transplant. Upcoming trials include novel antibody therapies for multiple myeloma. Dr. Gasparetto is also an investigator on several other clinical trials for myeloma including non-myeloablative allogeneic transplantation, high dose sequential chemotherapy and autologous peripheral blood stem cell transplantation and transplantation of partially HLA matched unrelated cord blood.

In Their Words

Education and Training

  • Fellow in Hematology/Oncology, Medicine, Duke University, 1996 - 1999
  • Medical Resident, Medicine, Duke University, 1993 - 1996
  • M.D., Sapienza University of Rome (Italy), 1986

Publications

Abonour, R, Wagner, L, Durie, BGM, Jagannath, S, Narang, M, Terebelo, HR, Gasparetto, CJ, Toomey, K, Hardin, JW, Kitali, A, Gibson, CJ, Srinivasan, S, Swern, AS, and Rifkin, RM. "Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry.(Accepted)" Annals of Hematology 97, no. 12 (December 2018): 2425-2436.

PMID
30056582
Full Text

Zheng, J, Sha, Y, Roof, L, Foreman, O, Lazarchick, J, Venkta, JK, Kozlowski, C, Gasparetto, C, Chao, N, Ebens, A, Hu, J, and Kang, Y. "Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade." Cancer Letters 440-441 (October 9, 2018): 1-10.

PMID
30312729
Full Text

Sivaraj, D, Green, MM, Kang, Y, Long, GD, Rizzieri, DA, Li, Z, Garrett, AH, McIntyre, JL, Chao, NJ, and Gasparetto, C. "Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma." Blood Cancer Journal 8, no. 8 (July 31, 2018): 71-null.

PMID
30065277
Full Text

Rifkin, RM, Jagannath, S, Durie, BGM, Narang, M, Terebelo, HR, Gasparetto, CJ, Toomey, K, Hardin, JW, Wagner, L, Parikh, K, Abouzaid, S, Srinivasan, S, Kitali, A, Zafar, F, and Abonour, R. "Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry." Clinical Therapeutics 40, no. 7 (July 23, 2018): 1193-1202.e1. (Review)

PMID
30007443
Full Text

Jagannath, S, Abonour, R, Durie, BGM, Gasparetto, C, Hardin, JW, Narang, M, Terebelo, HR, Toomey, K, Wagner, L, Srinivasan, S, Kitali, A, Yue, L, Flick, ED, Agarwal, A, and Rifkin, RM. "Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016)." Clinical Lymphoma, Myeloma & Leukemia 18, no. 7 (July 2018): 480-485.e3.

PMID
29844008
Full Text

Sundaramoorthy, P, Gasparetto, C, and Kang, Y. "The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation." Cancer Medicine (May 15, 2018).

PMID
29761903
Full Text

Kumar, SK, Dispenzieri, A, Fraser, R, Mingwei, F, Akpek, G, Cornell, R, Kharfan-Dabaja, M, Freytes, C, Hashmi, S, Hildebrandt, G, Holmberg, L, Kyle, R, Lazarus, H, Lee, C, Mikhael, J, Nishihori, T, Tay, J, Usmani, S, Vesole, D, Vij, R, Wirk, B, Krishnan, A, Gasparetto, C, Mark, T, Nieto, Y, Hari, P, and D'Souza, A. "Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time." Leukemia 32, no. 4 (April 2018): 986-995.

PMID
29263438
Full Text

Htut, M, D'Souza, A, Krishnan, A, Bruno, B, Zhang, M-J, Fei, M, Diaz, MA, Copelan, E, Ganguly, S, Hamadani, M, Kharfan-Dabaja, M, Lazarus, H, Lee, C, Meehan, K, Nishihori, T, Saad, A, Seo, S, Ramanathan, M, Usmani, SZ, Gasparetto, C, Mark, TM, Nieto, Y, and Hari, P. "Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 24, no. 3 (March 2018): 478-485.

PMID
29079457
Full Text

Zheng, Z, Fan, S, Zheng, J, Huang, W, Gasparetto, C, Chao, NJ, Hu, J, and Kang, Y. "Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma." Journal of hematology & oncology 11, no. 1 (February 27, 2018): 29-.

PMID
29482577
Full Text

Sivaraj, D, Bacon, W, Long, GD, Rizzieri, DA, Horwitz, ME, Sullivan, KM, Kang, Y, Li, Z, Chao, NJ, and Gasparetto, C. "High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma." Bone marrow transplantation 53, no. 1 (January 2018): 34-38.

PMID
29084203
Full Text

Pages